Skip to main content

Table 6 Added predictive value of biomarkers over already known predictors for time-averaged disease activity (DAS28) over 5 years of treatment

From: The relation between cartilage biomarkers (C2C, C1,2C, CS846, and CPII) and the long-term outcome of rheumatoid arthritis patients within the CAMERA trial

Item

B

95% CI

Standardized beta

P

R 2

Intercept

1.90

0.99 to 2.81

 

0.000

 

Treatment strategy

-0.29

-0.62 to 0.03

-0.16

0.076

0.076

RF positive

0.35

0.02 to 0.68

0.18

0.040

0.098

Baseline disease activity

0.25

0.10 to 0.40

0.30

0.001

0.169

EULAR good response

-0.84

-1.30 to -0.37

-0.46

0.001

 

EULAR moderate response

-0.19

-0.64 to 0.25

-0.11

0.393

0.322

CPII change 1 yr to baseline

0.18

-0.08 to 0.43

0.12

0.178

0.335

  1. EULAR nonresponse was used as reference category. 95% CI, 95% confidence interval; RF, rheumatoid factor.